Global Adoption FDNA’s AI-powered phenotyping platform is already used by a majority of clinical geneticists across thousands of sites in more than 130 countries, signaling a scalable entry point for partnerships with large hospital networks, genetics labs, and international research consortia seeking standardized genomic-phenotypic analysis.

Strategic Partnerships FDNA has a proven history of partnering with ThinkGenetic, Ambry Genetics, and Greenwood Genetic Center, indicating strong potential for co-sell arrangements, channel partnerships, and rapid access to established clinical ecosystems.

Data Advantage A deep, crowdsourced phenotypic and genotypic database paired with leading AI decision-support creates a durable moat that can be monetized via data licensing, collaborative research, and expanded precision medicine workflows for rare disease cohorts.

Rare Disease ROI With a focus on accelerating rare disease diagnoses and improving patient outcomes, FDNA offers clinics a compelling ROI through faster, more accurate genomic evaluations, creating a strong value proposition for hospital systems and specialty genetics labs pursuing diagnostic efficiency.

Growth Readiness As a small, globally deployed platform with broad reach, FDNA can scale by targeting mid-sized hospitals, regional labs, and CROs seeking scalable AI-assisted diagnostic tools, while expanding beyond facial phenotyping into broader phenotypic analysis.